fig2
From: PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
Figure 2. PARP inhibitor targets
Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Navigation
Committee on Publication Ethics
https://members.publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/
